Pulse Biosciences, Inc.

NASDAQ:PLSE

Medical - Instruments & Supplies

Healthcare
$45.83 +3.83%

+$0.97 today

Market cap
$3.37B
Beta
1.66
P/E (TTM)
-24.0
EPS (TTM)
-$1.10
52W Low $12.56High $28.53

Volume 0.33M

Average 0.31M

PLSE Cost of Revenue

Direct costs of producing the goods and services sold, such as materials, manufacturing, and service delivery.

Pulse Biosciences, Inc.NASDAQ: PLSE

Cost of Revenue · Q2 FY2026 · quarter ended Jun 2026

Cost of revenue grows, but more slowly than its trailing trend

Q2 FY2026 cost of revenue of $273K rose 2.2% year over year, behind the +439.7% change in trailing-twelve-month cost of revenue. Sequentially, it fell 26.2% from the prior quarter. Over 3 fiscal years it compounded at -48.7% a year.

Context

  • Cost of revenue amounted to 460.0% of revenue in FY2025.
  • Cost of revenue increased in 1 of the last 3 fiscal years.

What to watch

Whether quarterly growth recovers from +2.2% toward the trailing-twelve-month pace of +439.7%.

Sources:Income StatementText generated from reported figures; not investment advice.

Latest quarterJun 2026
$273K-26.2% QoQ
Last fiscal yearDec 2025
$1.61M— YoY
LTMJun 2026
$1.44M+439.7% YoY
Cost of Revenue past and forecast growth by horizon
Horizon Past Forecast Difference
Quarter+2.2%——
1 year———
3-year CAGR-48.7%——
5-year CAGR——
10-year CAGR——

Cost of Revenue history

USD · from the income statement

Latest · FY2025
1.61M USD
Year-over-year change
—
4-year CAGR
-4.9%

Cost of Revenue vs competitors

How PLSE compares with its peers on the latest reported figures

  • Peers report in different currencies, so cost of revenue is compared through growth and share of revenue rather than absolute size.
  • Its year-over-year change of +439.7% is the highest of 10, against a peer median of -5.7%.
  • Cost of revenue amounts to 121.6% of revenue for PLSE, versus a peer median of 18.8%.
PLSE Competitors
Cost of Revenue for PLSE and competitors
Company Period LTM YoY 3-year CAGR% of revenue
OPKOPKO Health, Inc.LTM Mar 2026$449.04M USD-8.4%-12.5%77.3%
NVCRNovoCure LimitedLTM Mar 2026$167.29M USD+17.8%+13.3%24.8%
STAASTAAR Surgical CompanyLTM Apr 2026$68.44M USD-5.7%-2.2%23.6%
BBNXBeta Bionics, Inc.LTM Mar 2026$47.24M USD+46.8%—42.8%
KMTSKestra Medical Technologies, Ltd.LTM Jan 2026$42.91M USD+23.8%—51.2%
LFMDLifeMD, Inc.LTM Mar 2026$30.96M USD+10.1%+28.2%14.1%
PLSEPulse Biosciences, Inc.LTM Jun 2026$1.44M USD+439.7%-48.7%121.6%
ATAIAtai Beckley Inc.LTM Jun 2026$615K USD-96.7%+82.0%13.7%
NKTRNektar TherapeuticsLTM Jun 2026$347K USD-97.2%—0.6%
DNTHDianthus Therapeutics, Inc.LTM Jun 2026$76K USD——4.0%
IMTXImmatics N.V.LTM Mar 2026€0 EUR-100.0%—0.0%
Peer median (excluding PLSE) —-5.7%+13.3%18.8%

Competitors are the stored peer set for PLSE. Fiscal calendars differ, so each company's latest period is shown. Text is generated from reported figures; not investment advice.

Income Statement

USD
Metric
FY2021
Dec 2021
FY2022
Dec 2022
FY2023
Dec 2023
FY2024
Dec 2024
FY2025
Dec 2025
Revenue1.42M700K00350K
Cost of Revenue1.97M11.94M1.21M01.61M
Gross Profit(550K)(11.24M)(1.21M)0(1.26M)
Gross Margin-38.8%-1606.3%——-360.0%
Research & Development28.64M20.84M27.8M32.34M44.72M
Selling, General & Admin33.82M25.97M15.78M23.92M32.03M
Operating Expenses62.46M46.81M42.37M56.26M75.68M
Depreciation & Amortization1.15M1.36M1.21M1.18M1.07M
EBITDA(62.51M)(57.15M)(39.9M)(52.41M)(71.71M)
EBITDA Margin-4408.6%-8164.3%——-20488.6%
Operating Income(63.01M)(58.06M)(43.57M)(56.26M)(76.94M)
Operating Margin-4443.9%-8293.9%——-21982.6%
Interest Income002.46M2.67M4.21M
Interest Expense646K448K1.1M00
Other Income / Expenses(646K)(448K)1.36M2.67M4.16M
Income Before Tax(63.66M)(58.51M)(42.21M)(53.59M)(72.78M)
Pre-Tax Margin-4489.4%-8357.9%——-20794.6%
Income Tax Expense00000
Net Income(63.66M)(58.51M)(42.21M)(53.59M)(72.78M)
Net Margin-4489.4%-8357.9%——-20794.6%
EPS (Basic)(2.28)(1.72)(0.88)(0.92)(1.08)
EPS (Diluted)(2.28)(1.72)(0.88)(0.92)(1.08)
Weighted Avg Shares27.96M33.94M48.04M58.4M67.4M
Weighted Avg Shares (Diluted)27.96M33.94M48.04M58.4M67.4M

Pulse Biosciences, Inc.

NASDAQ:PLSE

Intrinsic Alpha fair value

Locked

Current Price

$45.83

Margin of safety hidden

Unlock the intrinsic value to see where the current price sits on the valuation runway.

Valuation runway

Locked

Get the intrinsic value and margin of safety with a free account.